THE TGA has approved Yorvipath (palopegteriparatide) for the treatment of chronic hypoparathyroidism in adults, the first and only medicine to be listed on the ARTG for thisindication.
Hypoparathyroidism is a rare endocrine disease, where the production of parathyroid hormone is abnormally low or absent, causing low levels of calcium (hypocalcaemia) and high levels of phosphorous (hyperphosphataemia) in theblood.
"The lack of effective therapeutic options has been an urgent medical need in this area, and the local approval of Yorvipath represents an important advance in the treatment of chronic hypoparathyroidism in Australia," said endocrinology Professor Peter Ebeling.
Until now, the only treatment option has been conventional therapy with calcium and active vitaminD supplementation to keep blood calcium levels normal.
Yorvipath is distributed in Australia by Specialised Therapeutics, and the company's application for PBS listing of the drug will be considered at the upcoming PBACmeeting.
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Feb 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Feb 25
